

1800 Alta Vista Drive Ottawa ON K1G 4J5 Canada

## **INFORMATION ONLY**

Hizentra® 20% Liquid 20 mL (4g) Pre-filled Syringe Availability

Customer Letter # 2021-25

2021-05-03

Dear Colleagues:

Canadian Blood Services is pleased to share that the 20 mL (4g) pre-filled syringe (PFS) for Hizentra<sup>®</sup>, Subcutaneous Immunoglobulin (Human) (SCIg) 20% solution, will soon be available for ordering. Please refer to the attached CSL Behring Canada letter and CSL Hizentra 20 mL PFS fact sheet for additional information.

The transition from vials to pre-filled syringe will occur by end of June 2021, subject to utilization. Canadian Blood Services will manage existing vial format inventories to near depletion prior to introducing the PFS to customers for a gradual approach.

CBS Code	Product / Manufacturer	Vial Size
1000108062	Hizentra <sup>®</sup> pre-filled syringe, CSL Behring	20 mL (4g)

Revisions have been made to the following documents and more information can be found at <u>www.blood.ca</u> in the "Hospital Services" section.

- Plasma Protein Products Customer Table of Information
- Volume Expanders / Immune Globulins & S/D Plasma Order Form

## As a reminder:

**Unless there is a medical reason, all new SCIG patients should be started on Cuvitru®.** Volumes of Hizentra® and Cutaquig® are relatively small. These volumes are intended for patients who are currently on these brands and any future patients who cannot tolerate Cuvitru®. To ensure sufficient supply for current and future patients of these alternative products, clinicians should continue to prescribe Cuvitru® as their main SCIg product. Canadian Blood Services appreciates all customers' efforts to respect the designated product selections for patient needs.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at <u>www.blood.ca</u> in the "Hospitals Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Mark Newligh

Mark Newburgh Director, Integrated Supply Chain Planning